Personalis Inc. (PSNL)
Summary
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.
Personalis, Inc. (PSNL) M&A Call Transcript
Personalis, Inc. (PSNL) M&A Call Transcript
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
Personalis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 85 | $541 | $1,076.1 | $535.1 | 98.91% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 73 | $605.61 | $1,023.46 | $417.85 | 69% |
| NA Nizar Araji National Bank Of Canada /FI/ | 85 | $1,139 | $1,203.6 | $64.6 | 5.67% |
| BG Bart Gancher Intech Investment Management LLC | 13,228 | $107,782.8 | $187,308.48 | $79,525.68 | 73.78% |
 Robert Bruce Robert Jeffrey Bruce is VP/Secretary at Bruce & Co Inc. | 233,000 | $544,080 | $3.27M | $2.73M | 501.26% |
Personalis Inc. (PSNL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Personalis Inc. ever had a stock split?
Personalis Inc. Profile
| Professional Services Industry | Industrials Sector | Christopher Hall CEO | NASDAQ (NMS) Exchange | 71535D106 CUSIP |
| US Country | 260 Employees | - Last Dividend | - Last Split | 20 Jun 2019 IPO Date |
Overview
Personalis, Inc. is a biotechnology firm, established in 2011 with its headquarters in Fremont, California, that specializes in the development and marketing of innovative cancer genomic tests and analytics. The company serves a broad international market, including regions such as the United States, Europe, and the Asia-Pacific. Personalis caters to the needs of pharmaceutical companies for translational research and biomarker discovery, aiding the development of personalized cancer therapies. Moreover, it provides sophisticated tests employed by physicians to identify cancer recurrence, monitor the evolution of the disease, and discover vital information for choosing appropriate therapy options. Its clientele encompasses pharmaceutical and biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and individual patients.
Products and Services
- NeXT Personal
- ImmunoID NeXT
- NeXT Personal Dx
- NeXT Dx
- Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)
This is a tumor-informed liquid biopsy test designed for the detection of minimal residual disease (MRD) and the recurrence of cancer. It enables personalized monitoring and treatment options by providing a deep insight into the molecular signature of an individual's cancer.
A tissue-based comprehensive test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data. Through advanced analytics, it offers a multi-dimensional view of the tumor and its microenvironment from a single sample, facilitating the development of targeted cancer therapies and immunotherapies.
Similar to NeXT Personal, this test offers tumor-informed liquid biopsy capabilities for the detection of MRD and cancer recurrence, specifically designed with a diagnostic focus to aid clinicians in the personalized treatment of cancer patients.
A comprehensive tumor profiling test that unlocks insights into the entire exome (DNA) and transcriptome (RNA) of a cancer patient. By providing matched tumor-normal analysis, it leverages detailed genomic information to better understand the disease and guide treatment options.
Personalis offers WES of cancer tissue and matched blood samples, and WGS on human samples for a variety of purposes including diagnostic tool development, research projects, and population sequencing initiatives. These services are complemented by the company’s sequencing and data analysis capabilities, supporting the broader research and medical community in uncovering new insights into cancer genomics.
